Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Options on this firm's blockbuster cost a little but pay off big.
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
We dive into the process for adding companies and booting them from the iconic index.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Week ending Oct. 27: Stocks held in check by jump oil prices, weak housing market.
This screen finds companies ready to take advantage when major provisions of law take effect in 2014.